John Renger Cerevel Therapeutics Holdings, Inc. (CERE) insider trading activity

CERE Quotes by TradingView

John Renger is Chief Scientific Officer of Cerevel Therapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of CERE, which is worth approximately $0. The most recent transaction as insider was on Mar 16, 2022, when has been sold 25,000 shares (Common Stock) at a price of $30.0 per share, resulting in proceeds of $750,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
100.0% 12M change
Total Value Held $0

John Renger Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 16 2022
SELL
Open market or private sale
$750,000 $30.0 p/Share
25,000 Reduced 92.66%
1,980 Common Stock
Mar 16 2022
BUY
Exercise of conversion of derivative security
$87,500 $3.5 p/Share
25,000 Added 48.1%
26,980 Common Stock
Mar 09 2022
SELL
Open market or private sale
$1,012,500 $33.75 p/Share
30,000 Reduced 93.81%
1,980 Common Stock
Mar 09 2022
BUY
Exercise of conversion of derivative security
$105,000 $3.5 p/Share
30,000 Added 48.4%
31,980 Common Stock
Mar 02 2022
SELL
Open market or private sale
$750,000 $30.0 p/Share
25,000 Reduced 92.66%
1,980 Common Stock
Mar 02 2022
BUY
Exercise of conversion of derivative security
$87,500 $3.5 p/Share
25,000 Added 48.1%
26,980 Common Stock
Feb 09 2022
SELL
Open market or private sale
$750,000 $30.0 p/Share
25,000 Reduced 92.66%
1,980 Common Stock
Feb 09 2022
BUY
Exercise of conversion of derivative security
$87,500 $3.5 p/Share
25,000 Added 48.1%
26,980 Common Stock
Dec 27 2021
SELL
Open market or private sale
$144,445 $35.0 p/Share
4,127 Reduced 67.58%
1,980 Common Stock
Dec 27 2021
BUY
Exercise of conversion of derivative security
$14,444 $3.5 p/Share
4,127 Added 40.33%
6,107 Common Stock
Dec 23 2021
SELL
Open market or private sale
$205,555 $35.0 p/Share
5,873 Reduced 74.79%
1,980 Common Stock
Dec 23 2021
BUY
Exercise of conversion of derivative security
$20,556 $3.5 p/Share
5,873 Added 42.79%
7,853 Common Stock
Dec 21 2021
SELL
Open market or private sale
$237,250 $32.5 p/Share
7,300 Reduced 78.66%
1,980 Common Stock
Dec 21 2021
BUY
Exercise of conversion of derivative security
$25,550 $3.5 p/Share
7,300 Added 44.03%
9,280 Common Stock
Dec 17 2021
SELL
Open market or private sale
$231,465 $32.5 p/Share
7,122 Reduced 78.25%
1,980 Common Stock
Dec 17 2021
BUY
Exercise of conversion of derivative security
$24,927 $3.5 p/Share
7,122 Added 43.9%
9,102 Common Stock
Dec 16 2021
SELL
Open market or private sale
$181,285 $32.5 p/Share
5,578 Reduced 73.8%
1,980 Common Stock
Dec 16 2021
BUY
Exercise of conversion of derivative security
$19,523 $3.5 p/Share
5,578 Added 42.46%
7,558 Common Stock
Dec 15 2021
SELL
Open market or private sale
$750,500 $30.02 p/Share
25,000 Reduced 92.66%
1,980 Common Stock
Dec 15 2021
BUY
Exercise of conversion of derivative security
$87,500 $3.5 p/Share
25,000 Added 48.1%
26,980 Common Stock
Nov 10 2021
SELL
Open market or private sale
$2,226,400 $40.48 p/Share
55,000 Reduced 100.0%
0 Common Stock
Nov 10 2021
BUY
Exercise of conversion of derivative security
$192,500 $3.5 p/Share
55,000 Added 50.0%
55,000 Common Stock
JR

John Renger

Chief Scientific Officer
Cambridge, MA

Track Institutional and Insider Activities on CERE

Follow Cerevel Therapeutics Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERE shares.

Notify only if

Insider Trading

Get notified when an Cerevel Therapeutics Holdings, Inc. insider buys or sells CERE shares.

Notify only if

News

Receive news related to Cerevel Therapeutics Holdings, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CERE